Alexion Pharmaceuticals, Inc. to Join the NASDAQ-100 Index Beginning April 4, 2011

NEW YORK, March 29, 2011 (GLOBE NEWSWIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) will become a component of the NASDAQ-100 Index® (Nasdaq:NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq:NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq:NDXX) prior to market open on Monday, April 4, 2011. Alexion Pharmaceuticals, Inc. will replace Genzyme Corporation (Nasdaq:GENZ).

Alexion is headquartered in Cheshire, Connecticut and has a market capitalization of approximately $8.5 billion. For more information about the company, go to www.alexionpharm.com.

The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world.

The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with approximately 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. Please follow NASDAQ OMX on Facebook (http://www.facebook.com/nasdaqomx) and Twitter (http://www.twitter.com/nasdaqomx).

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investors should undertake their own due diligence and carefully evaluate companies before investing.

NDAQO

CONTACT: Media Contact: Wayne Lee, NASDAQ +1.301.978.4875 Issuer & Investor Contact: Lisa Chaney, NASDAQ +1.301.978.8281

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NDAQ